Adaptive Biotechnologies Corp- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Adaptive Biotechnologies Corp 公司

Adaptive Biotechnologies Corporation 是一家商業階段的生物技術公司。該公司專注於利用適應性免疫系統的固有生物學來改變疾病的診斷和治療。其免疫醫學平臺應用其專有技術來讀取患者免疫系統的多種遺傳密碼，並準確瞭解免疫系統如何檢測和治療該患者的疾病。該公司的業務主要圍繞兩個領域：淋巴惡性腫瘤中微小殘留病 (MRD) 的臨牀評估和免疫醫學 (IM) 驅動的藥物發現和開發。MRD 業務專注於使用其高靈敏度的下一代測序 (NGS) 檢測來測量血液系統惡性腫瘤患者的 MRD。該公司包括向臨牀醫生提供的 clonoSEQ 臨牀診斷測試和向生物製藥合作伙伴提供的 clonoSEQ 檢測，以推進藥物開發工作 (MRD Pharma)。

公司簡介

公司代碼ADPT

公司名稱Adaptive Biotechnologies Corp

上市日期Jun 27, 2019

成立日期2009

CEOMr. Chad M. Robins

員工數量619

證券類型Ordinary Share

年結日Jun 27

公司地址1165 Eastlake Ave E

城市SEATTLE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編98109

電話12066590067

網址https://www.adaptivebiotech.com

公司代碼ADPT

上市日期Jun 27, 2019

成立日期2009

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Chad M. Robins

Chairman of the Board, Chief Executive Officer, Co-Founder

2.10M

-4.49%

Ms. Susan Bobulsky

Chief Commercial Officer - MRD

347.24K

+37.09%

Mr. Francis Lo

Chief People Officer

332.85K

+31.17%

Mr. Peter M. Neupert

Lead Independent Director

209.30K

+8.24%

Dr. Sharon Benzeno, Ph.D.

Chief Commercial Officer - Immune Medicine

95.93K

-15.18%

Dr. Katey Einterz Owen, Ph.D.

Independent Director

57.23K

+42.41%

Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.

Independent Director

54.30K

+41.54%

Mr. Kyle Piskel

Chief Financial Officer

47.39K

-3.91%

Ms. Karina Calzadilla

Vice President - Investor Relations

--

Ms. Julie Rubinstein

President, Chief Operating Officer

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Chad M. Robins

Chairman of the Board, Chief Executive Officer, Co-Founder

2.10M

-4.49%

Ms. Susan Bobulsky

Chief Commercial Officer - MRD

347.24K

+37.09%

Mr. Francis Lo

Chief People Officer

332.85K

+31.17%

Mr. Peter M. Neupert

Lead Independent Director

209.30K

+8.24%

Dr. Sharon Benzeno, Ph.D.

Chief Commercial Officer - Immune Medicine

95.93K

-15.18%

Dr. Katey Einterz Owen, Ph.D.

Independent Director

57.23K

+42.41%

收入明細

單位: USD更新時間: 4月6日週日

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

MRD revenue

145.53M

81.32%

Immune meidicine revenue

33.43M

18.68%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

MRD revenue

145.53M

81.32%

Immune meidicine revenue

33.43M

18.68%

股東統計

更新時間: 6月11日週三

持股股東

股東類型

持股股東

佔比

Viking Global Investors LP

19.74%

Rubric Capital Management LP

8.63%

The Vanguard Group, Inc.

7.32%

BlackRock Institutional Trust Company, N.A.

6.45%

Columbia Threadneedle Investments (US)

4.27%

Other

53.59%

持股股東

佔比

Viking Global Investors LP

19.74%

Rubric Capital Management LP

8.63%

The Vanguard Group, Inc.

7.32%

BlackRock Institutional Trust Company, N.A.

6.45%

Columbia Threadneedle Investments (US)

4.27%

Other

53.59%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

53.09%

Investment Advisor

23.82%

Hedge Fund

17.68%

Individual Investor

2.66%

Research Firm

2.15%

Private Equity

0.68%

Venture Capital

0.40%

Bank and Trust

0.30%

Pension Fund

0.28%

機構持股

更新時間: 2月22日週六

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

476

143.19M

94.26%

-9.97M

2024Q4

481

143.31M

96.47%

-18.10M

2024Q3

478

143.38M

97.20%

-27.99M

2024Q2

486

149.83M

101.63%

-16.40M

2024Q1

506

146.67M

99.58%

-10.66M

2023Q4

529

145.23M

100.12%

-16.05M

2023Q3

531

142.64M

98.54%

-11.65M

2023Q2

545

137.84M

95.31%

-15.76M

2023Q1

577

135.96M

94.24%

-11.97M

2022Q4

616

132.93M

92.90%

-17.07M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Viking Global Investors LP

29.99M

20.19%

--

Dec 31, 2024

Rubric Capital Management LP

14.60M

9.83%

+200.00K

+1.39%

Dec 31, 2024

The Vanguard Group, Inc.

10.69M

7.19%

+47.48K

+0.45%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

9.81M

6.6%

+55.67K

+0.57%

Dec 31, 2024

Nikko Asset Management Co., Ltd.

6.83M

4.6%

-900.75K

-11.65%

Dec 31, 2024

ARK Investment Management LLC

9.42M

6.34%

-2.18M

-18.77%

Dec 31, 2024

Millennium Management LLC

6.29M

4.24%

-3.11M

-33.06%

Dec 31, 2024

Aristotle Atlantic Partners, LLC

2.89M

1.94%

-114.50K

-3.82%

Dec 31, 2024

持股ETF

更新時間: 6月6日週五

機構名稱

佔比

ARK Genomic Revolution ETF

4.33%

ROBO Global Healthcare Technology & Innovation ETF

1.82%

Franklin Genomic Advancements ETF

1.53%

First Trust Small Cap Growth AlphaDEX Fund

0.84%

Invesco NASDAQ Future Gen 200 ETF

0.7%

First Trust Nasdaq Lux Digi Health Solutions ETF

0.49%

Invesco Dorsey Wright SmallCap Momentum ETF

0.49%

First Trust Small Cap Core Alphadex Fund

0.41%

iShares Micro-Cap ETF

0.2%

Invesco Nasdaq Biotechnology ETF

0.14%

ARK Genomic Revolution ETF

佔比4.33%

ROBO Global Healthcare Technology & Innovation ETF

佔比1.82%

Franklin Genomic Advancements ETF

佔比1.53%

First Trust Small Cap Growth AlphaDEX Fund

佔比0.84%

Invesco NASDAQ Future Gen 200 ETF

佔比0.7%

First Trust Nasdaq Lux Digi Health Solutions ETF

佔比0.49%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0.49%

First Trust Small Cap Core Alphadex Fund

佔比0.41%

iShares Micro-Cap ETF

佔比0.2%

Invesco Nasdaq Biotechnology ETF

佔比0.14%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Adaptive Biotechnologies Corp

12.390USD

Adaptive Biotechnologies Corp

12.390

概覽

公司